HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy | Zendy

Bart Fevery | Zendy; S. Süsser | Zendy; Oliver Lenz | Zendy; Gavin Cloherty | Zendy; D. Perner | Zendy; Gastón Picchio | Zendy; Christoph Sarrazin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy

Author(s) -

Bart Fevery,

S. Süsser,

Oliver Lenz,

Gavin Cloherty,

D. Perner,

Gastón Picchio,

Christoph Sarrazin

Publication year - 2013

Publication title -

antiviral therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.747

H-Index - 87

eISSN - 2040-2058

pISSN - 1359-6535

DOI - 10.3851/imp2760

Subject(s) - protease inhibitor (pharmacology) , medicine , viral load , virology , pharmacology , biology , antiretroviral therapy , virus

Response-guided therapy (RGT) for HCV treatment, whereby therapy duration is shortened according to on-treatment virological response, requires patient HCV RNA concentrations below the lower limit of quantification (LLOQ) or limit of detection (LOD) of the viral load assay at weeks 4 and 12. Concordance of two assays and impact on treatment decisions were investigated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research